• Olivia

Global Digital PCR Market Size to grow by US$ 935.3 Million in 2030

The digital PCR market is projected to grow USD 935.3 Million in 2030, at a CAGR of 7.4%. The rising incidence of various malignancies, including lung cancer, blood cancer, and brain tumors, is a prominent factor driving the growth of the global digital polymerase chain reaction market. Cancer is diagnosed molecularly via digital PCR tests. For instance, according to the Globocan 2020, lung cancer has an expected 477,534 newly diagnosed patients and is the second most common cancer in Europe. Furthermore, the advantages over traditional PCR technology, such as real-time polymerase chain reaction (RT-PCR) and quantitative polymerase chain reaction (qPCR) are anticipated to drive the growth of the market. Additionally, rising healthcare costs for individuals in underdeveloped nations and rising demand for precise molecular identification of disease is fueling the digital PCR market growth.

Digital PCR Market

Request Free Sample To Learn More About This Report

The surging R&D into novel genetic technologies and product development has been accelerated by the growing customer demand for early disease detection and treatment. An increase in investments, as well as the availability of money and grants, have contributed to this surge in R&D activities. Additionally, qPCR and dPCR products are becoming more and more appreciated by governmental and federal organizations around the world for their use in genomics-based research. The qPCR and dPCR sector have seen a number of financing initiatives by public and private organizations to assist genomic research over the last decade.

The introduction of new products by major companies together with technological breakthroughs in PCR technologies are fueling the market's expansion. For instance, some industry participants have created unique qPCR and dPCR technologies that can recognize various infections or detect a variety of genetic alterations.

Request Free Sample To Learn More About This Report

The droplet segment is dominating the market share of global digital PCR market owing to technological advancements and numerous new product releases by leading players. For instance, Merck KGaA introduced the BioReliance Droplet dPCR Technology for the development of cell and gene therapies in August 2018. The pharmaceuticals & biotechnology industries segment is dominating the market share of global digital PCR market owing to an increase in cancer patients.

North America is dominating the market share of global digital PCR market owing to infectious disease prevalence and high diagnostic rates in the area. In addition, the region is dominating the market due to the high patient population awareness of novel diagnostic choices and the availability of modern dPCR devices in the area. Furthermore, the market expansion in the region is being driven by the increasing prevalence of numerous cancers and metabolic illnesses that call for cutting-edge diagnostics and treatments.

Request Free Sample To Learn More About This Report


August 2022- Bio-Rad Laboratories acquired Curiosity Diagnostics to bring a new generation of rapid PCR systems to market.

July 2022- QIAGEN announced the launch of a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers, particularly those involved in the biopharma industry.

April 2022- Stilla has made a co-marketing agreement with Promega Corporation to offer complete dPCR solution which combines sample preparation with the latest Maxwell systems and digital PCR on the six-color naica system. It will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery.

January 2022- JN Medsys develops a PCR test kit that specifically detects the Omicron variant with high accuracy.

August 2018- Merck Introduced BioReliance Droplet Digital Polymerase Chain Reaction (ddPCR) technology for tittering viral products, including recombinant Adenovirus, Adeno-Associated Virus, Lentivirus and Retrovirus and other vectors used in cell and gene therapy development.

Read More Details On This Report: https://www.extrapolate.com/Healthcare-Medical-Devices-Biotechnology/digital-pcr-market/26057